Teclistamab-Daratumumab in AL Amyloidosis

Suzanne Lentzsch, MD

Status and phase: Enrolling; Phase 2

Conditions: Amyloid Light-chain Amyloidosis

Treatments: Drug: Teclistamab; Drug: Daratumumab and Hyaluronidase-fihj

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT07110844

AAAV8827

1452862 (Other Grant/Funding Number)

Details and patient eligibility

About

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.

The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.

Full description

The purpose of this study is to assess the effectiveness and safety of teclistamab-daratumumab combination in newly diagnosed AL amyloidosis. The study aims to evaluate whether this combination is able to effectively decrease the level of toxic amyloid-producing light chains circulating in the participants' blood, with the overarching goal of avoiding organ damage, improving organ function, and prolonging life.

Enrollment: 25 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age >18 years and able to sign Informed Consent Form (ICF). If the individual being considered for participation in this study is unable to provide informed consent due to medical, cognitive, or other conditions, a legally authorized representative (LAR) may consent on their behalf.

2. Ability to comply with the study protocol, in the investigator's judgment.

3. Confirmed histopathological diagnosis of systemic AL amyloidosis by mass spectrometry or immunohistochemistry (IHC) or Immunofluorescence (IF) on a tissue biopsy that is positive for Congo Red.

4. Patient must not have received any prior plasma cell clone-directed therapy.

5. Measurable hematologic disease, defined as one of the following:

   1. Difference between involved and uninvolved serum free light chain (dFLC) ≥50 mg/L and/or 5 mg/dL
   2. Serum M-protein ≥0.5 g/dL on protein electrophoresis

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

7. One or more organs involved by AL amyloidosis as per consensus guidelines

8. Pre-treatment clinical laboratory values meeting the following criteria during the screening phase:

   1. Absolute neutrophil count ≥0.75 × 10^9/L
   2. Hemoglobin level ≥8.0 g/dL; red blood cell transfusion allowed until 7 days before C1D0.
   3. Platelet count ≥50 × 10^9/L; Platelet transfusions are acceptable without restriction during the Screening period
   4. Alanine aminotransferase level (ALT) ≤2.5 times the Upper Limit of Normal (ULN)
   5. Aspartate aminotransferase (AST) ≤2.5 times the ULN
   6. Total bilirubin level ≤1.5 × ULN except for subjects with Gilbert syndrome, in which case direct bilirubin ≤2 × ULN
   7. Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73 m^2, measured by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

9. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs.

For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.

Exclusion criteria

1. Prior therapy for AL amyloidosis or multiple myeloma with the exception of 160 mg dexamethasone (or equivalent corticosteroid) maximum exposure prior to C1D0.

2. Patients meeting criteria for symptomatic multiple myeloma by any one of the following: (a) Lytic lesions on imaging (Skeletal survey, whole body CT or MRI, or PET/CT) (b) Plasmacytoma, (c) Hypercalcemia without any alternate etiology, (d) Bone marrow plasma cell infiltrate of greater than 60%.

   Patients with involved/uninvolved serum FLC ratio>100 as the sole myeloma-defining event will be allowed.

3. Evidence of significant cardiovascular conditions as specified below:

   1. NT-Pro BNP > 8500 pg/mL, and/or
   2. NYHA Class IIIb or IV functional class

4. History of other malignancy that could affect compliance with the protocol or interpretation of results.

   Patients with a history of curatively treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, breast cancer, or Hodgkin's Lymphoma are generally eligible. Patients with a malignancy that has been treated, but not with curative intent, will be excluded, unless the malignancy has been in remission without treatment for ≥ 2 years prior to enrollment.

5. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal).

6. Patients on renal replacement therapy

7. Patients with HIV who are not on HAART or those with active hepatitis A, B, or C infection.

8. Planned stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permitted, as per investigators' discretion.

9. Known hypersensitivity to any of the agents

10. Patients who are receiving any other investigational agent concurrently.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

Teclistamab-Daratumumab

Experimental group

Description:

All participants in this study will receive teclistamab and daratumumab.

Treatment:

Drug: Daratumumab and Hyaluronidase-fihj

Drug: Teclistamab